 |
|
|
| |
Week 96 results of the phase 3, randomized, non-inferiority EMERALD trial:
Efficacy and safety of switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in virologically suppressed adults living with HIV-1
|
| |
| |
Reported by Jules Levin
IDWeek 2018, October 3-7, 2018, San Francisco
Joseph J. Eron1, Chloe Orkin2, Douglas Cunningham3, Federico Pulido4, Frank A. Post5,
Stéphane De Wit6, Erkki Lathouwers7, Veerle Hufkens7, Romana Petrovic7, Erika Van Landuyt7,
on behalf of the EMERALD study group
1The University of North Carolina School of Medicine, Chapel Hill, NC; 2Department of Infection and Immunity, Royal London Hospital and Queen Mary University, Barts Health NHS Trust, London, UK;
3Pueblo Family Physicians, Phoenix, AZ, USA; 4HIV Unit, Hospital 12 de Octubre, imas12, UCM, Madrid, Spain; 5King's College Hospital NHS Foundation Trust, London, United Kingdom; 6Saint-Pierre University Hospital, Université Libre de Bruxelles, Brussels, Belgium; 7Janssen Pharmaceutica NV, Beerse, Belgium
|
| |
|
|
|
|
|
